新型口服抗凝药的拮抗剂研究进展

Recent Advances in Antagonist of New Oral Anticoagulants

新型口服抗凝药可用于心房颤动患者的卒中预防和静脉血栓栓塞性疾病的治疗。与维生素K拮抗剂相比,新型口服抗凝药的相关出血事件较少,但当出血发生时,医生评估和管理新型口服抗凝药相关性出血的能力仍值得关注。简介依达赛珠单抗、andexanet alfa、ciraparantag、凝血酶原复合物、活化凝血酶原复合物和重组因子Ⅶa等用于止血或逆转新型口服抗凝药抗凝作用的药物研究进展,以期为新型口服抗凝药的临床应用及相关出血事件的处理提供参考。

New oral anticoagulants(NOACs) are used for the prevention of stroke in patients with atrial fibrillation and treatment of venous thromboembolism. Although the incidence of bleeding induced by NOACs is lower than that induced by vitamin K antagonists, the physicians’ assessment and management of NOAC-related bleeding still remain a concern. This paper briefly reviews the research advances in the application of idarucizumab, andexanet alfa, ciraparantag, prothrombin complex concentrate(PCC), activated PCC(aPCC) and recombinant factor Ⅶa(rFⅦa) in hemostasis or reversal of anticoagulant effects of NOACs in order to provide reference for the clinical application of NOACs and treatment of related bleeding events.